Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document C2009/280/12

Prior notification of a concentration (Case COMP/M.5713 — Altor/Pharmacy Company Sweden 1 AB und Pharmacy Company Sweden 8 AB) — Candidate case for simplified procedure Text with EEA relevance

SL C 280, 20.11.2009, p. 32–32 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

20.11.2009   

EN

Official Journal of the European Union

C 280/32

Prior notification of a concentration

(Case COMP/M.5713 — Altor/Pharmacy Company Sweden 1 AB und Pharmacy Company Sweden 8 AB)

Candidate case for simplified procedure

(Text with EEA relevance)

2009/C 280/12

1.

On 13 November 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Altor Fund III GP Limited (as General Partner of Altor Fund III (No 1) Limited Partnership, Altor Fund III (No 2) Limited Partnership and as investment manager to Altor Fund III (No 3) Limited, Channel Islands) acquires, within the meaning of Article 3(1)(b) of the Council Regulation, by way of purchase of shares, sole control of Pharmacy Company Sweden 1 AB and Pharmacy Company Sweden 8 AB (Sweden).

2.

The business activities of the undertakings concerned are:

—

Altor Fund III is a private equity investment fund. The Altor funds consist of three private equity funds and their respective portfolios of acquired companies. The three Altor private equity funds (Altor 2003 Fund, Altor Fund II and Altor Fund III) focus on investments in the mid-market segment of the Nordic region and are active in a variety of industries,

—

Pharmacy Company Sweden 1 AB and Pharmacy Company 8 AB are fully owned subsidiaries of the Swedish state-owned limited liability company Apoteket AB, which has had the exclusive right to sell pharmaceuticals on the Swedish market.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 or 22967244) or by post, under reference number COMP/M.5713 — Altor/Pharmacy Company Sweden 1 AB und Pharmacy Company Sweden 8 AB, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

Top